KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Accumulated Expenses (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Accumulated Expenses data on record, last reported at $95.6 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 19.32% year-over-year to $95.6 million; the TTM value through Dec 2025 reached $95.6 million, up 19.32%, while the annual FY2025 figure was $95.6 million, 19.32% up from the prior year.
  • Accumulated Expenses reached $95.6 million in Q4 2025 per PCRX's latest filing, up from $79.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $127.6 million in Q4 2021 and bottomed at $50.2 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $73.4 million, with a median of $73.7 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: surged 79.72% in 2021, then decreased 29.7% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $127.6 million in 2021, then decreased by 29.61% to $89.8 million in 2022, then fell by 28.45% to $64.2 million in 2023, then increased by 24.72% to $80.1 million in 2024, then rose by 19.32% to $95.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $95.6 million in Q4 2025, $79.6 million in Q3 2025, and $71.0 million in Q2 2025.